Revenue Growth and Margin Expansion
In Q2 2025, revenue grew by 7% to $36 million, and gross margins expanded by 574 basis points to 55.2%. Adjusted EBITDA increased by 32% to $8 million with an improved margin of 427 basis points to 22.3%.
Significant Increase in Net Income and Cash Flow
Net income increased by 262%, and cash flows from operations more than doubled for the quarter and year-to-date. Operating cash flow for the first 6 months of 2025 was $8.7 million, up by $6 million from the prior year.
Strategic Stock Repurchases
Approximately $3.5 million was returned to shareholders through stock repurchases during the quarter, totaling $6.4 million for the first half of 2025.
Promising Outlook in Oncology and Device Solutions
Oncology continues to be a strong contributor to growth. Investments in Device Solutions are paying off, with a revenue increase of $3.5 million annually from a $5.2 million investment in devices.